Medical Cannabis for PTSD: A Patient Guide
Medical cannabis is not FDA-approved for PTSD, but many states allow it. Learn the evidence, card steps, product forms, and risks.
Short answer
No cannabis product is FDA-approved to treat PTSD. The FDA has approved two synthetic cannabinoids, dronabinol and nabilone, for chemotherapy-induced nausea and vomiting. Nabilone has been tested off-label for PTSD nightmares in small trials. The evidence base is thin: most studies enroll fewer than 100 people, run for weeks, and use different products, doses, and THC-to-CBD ratios.
What clinical trials have tested
- Nabilone: A 2015 randomized crossover trial of 10 patients with PTSD found nabilone reduced nightmares compared with placebo. The sample was small and each phase lasted 7 weeks.
- Smoked cannabis: A VA-funded randomized trial gave 80 veterans cannabis at three THC strengths, from under 0.03% to about 11%. PTSD symptom scores fell in every group, including placebo. The trial did not show a clear drug effect.
- CBD: No large randomized trial has shown CBD reduces core PTSD symptoms such as re-experiencing, avoidance, and hyperarousal. Several small trials are running.
- Observational studies: Surveys of medical cannabis patients with PTSD report less anxiety and better sleep. These designs rely on self-report and cannot separate drug effect from expectancy.
Guideline position
The 2023 VA/DoD clinical practice guideline recommends against cannabis for PTSD. It cites insufficient evidence of benefit and known risks: cannabis use disorder, memory and attention problems, and respiratory harm from smoke. Trauma-focused psychotherapy remains first-line.
medical cannabis for ptsd dosage
FDA status
Cannabis stays Schedule I under federal law. Researchers need a DEA registration, an FDA-authorized protocol, and a Schedule I license. Supply must come from registered growers. These steps add cost and months of delay, which is one reason trial sizes stay small.
Medical Cannabis for PTSD Therapy: Alternative Options Comparison
What a strong study measures
- Symptom scales: CAPS-5, a clinician interview, and PCL-5, a self-report form.
- Product detail: THC and CBD percentages and dose in milligrams.
- Route: smoked, vaporized, oral, or sublingual.
- Duration: 12 weeks or longer to test lasting change.
- Blinding: a placebo with trace THC or no THC.
- Safety endpoints: cannabis use disorder, anxiety, psychosis, and driving impairment.
Bottom line
Clinical studies do not support cannabis as a proven PTSD treatment. Findings are mixed and samples are small. Some patients report symptom relief, and PTSD is a qualifying condition in most state medical cannabis programs. A clinician should review symptoms, other medications, and mental health history before any use.